XML 89 R11.htm IDEA: XBRL DOCUMENT

Financial Instruments

6 Months Ended

Jun. 30, 2023

Investments, All Other Investments [Abstract]

Financial Instruments

5. Financial Instruments

Cash, Cash Equivalents, Restricted Cash and Marketable Securities

The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of June 30, 2023, and December 31, 2022:

		2023
						Unrealized Gain/				Fair				Cash and Cash				Marketable
		Cost				(Loss)				Value				Equivalents				Securities
Cash		$	9,971,000			$	-			$	9,971,000			$	9,971,000			$	-
Level 1
Money Market Funds		$	62,000				-				62,000				62,000				-
Marketable Securities			15,165,000				(3,590,000	)			11,575,000				-				11,575,000
Total		$	25,198,000			$	(3,590,000	)		$	21,608,000			$	10,033,000			$	11,575,000

		2022
						Unrealized Gain/				Fair				Cash and Cash				Marketable
		Cost				(Loss)				Value				Equivalents				Securities				Investments
Cash		$	19,226,000			$	-			$	19,226,000			$	19,226,000			$	-			$	-
Level 1
Money Market Funds			64,000				-				64,000				64,000				-				-
Marketable Securities			36,263,000				(3,659,000	)			27,307,000				-				27,307,000				-
Level 2
Warrants			3,318,000				-				140,000				-				-				140,000
Convertible securities			1,023,000				-				39,000				-				-				39,000
Total		$	59,894,000			$	(3,659,000	)		$	46,776,000			$	19,290,000			$	27,307,000			$	179,000

The Company typically invests with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual security in the investment portfolio.